CD47|SIRPα SUMMIT

CD47|SIRPα SUMMIT

April | Boston, MA.

Deep Dive into the Next Breakthrough Immuno-Oncology Target

Registration Agenda

2019 Partners

Partners
Mitra Biotech

Mitra Biotech’s CANscript™ is an ex-vivo translational platform that delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to support more effective and efficient oncology drug development decision making and to inform patient-specific cancer therapeutic selection.

 

Learn More

Eurofins DiscoverX

Eurofins DiscoverX, headquartered in Fremont, CA, USA, is a leader in the design and manufacture of biochemical and cell-based assays for the drug development and life science markets. This industry-leading portfolio of products, help to accelerate development of biologic and small molecule drugs, from discovery to QC lot release.

 

Learn More

KEY FEATURES
EXCLUSIVELY DEDICATED

This summit is the first to be solely dedicated to exploring only the CD47/SIRPα axis.

PIONEERING SPEAKER FACULTY

Hear from and meet the gurus of the field and the most exciting newcomers from biotech, academia and pharma.

CRUCIAL DISCUSSIONS

Differing approaches to targeting the CD47/SIRPα axis, key fundamental biology, Combination Therapies vs. Monotherapies and more will be dissected through interactive presentations and open Q&A.

SENIOR-LEVEL NETWORKING

Meet with industry influencers and decision-makers in this intimate and high-quality setting to generate genuinely impactful connections and takeaways.

Artboard 8
CURATED LEARNING JOURNEY

Travel from the known to the unknown and the simple to the complex through a carefully constructed end-to-end learning experience.

Finger-Hand-Tap-Touch Gestures-Counting-One
1 IMPACTFUL DAY

We know you’re busy people. That’s why the exclusive CD47|SIRPα Summit is purposely constructed as a one-day feast of inspiring learning with a jam-packed agenda.

WITH VERY PROMISING RESULTS FROM THE FIRST CLINICAL STUDIES, THE DEDICATED CD47/SIRPα SUMMIT IS PERFECTLY TIMED. THIS EVENT PROVIDES THE OPPORTUNITY FOR THOSE WHO HAVE PIONEERED THE SPACE AND ALSO THE NEWCOMERS OF THE INDUSTRY TO GET TOGETHER AND LEARN MORE ABOUT THIS DYNAMIC AND EXCITING FIELD.

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

THE CD47/SIRPα 2019 SUMMIT IS A VALUABLE OPPORTUNITY TO SHARE OUR LEARNINGS AND EXPLORE IMPORTANT QUESTIONS ABOUT TARGETING THE MYELOID CHECKPOINT PATHWAY FOR THE TREATMENT OF CANCER.

Hong Wan, Chief Scientific Officer, ALX Oncology

PHAGOCYTOSIS AND SPECIFICALLY THE CD47/SIRPα AXIS IS BECOMING A HOT TOPIC IN IO WITH ENCOURAGING PRE-CLINICAL AND INITIAL CLINICAL DATA. I LOOK FORWARD TO HEARING THE THOUGHT-PROVOKING PRESENTATIONS AND DISCUSSIONS FROM KEY CONTRIBUTORS AND EXPERTS IN THE FIELD, BOUGHT TOGETHER BY THE CD47/SIRPα 2019 SUMMIT.

Joern-Peter Halle, Senior Vice President, Head of TIP Immuno Oncology and Head of External Innovation, Merck KGaA

2019 Speakers

JOERN-PETER HALLE
JOERN-PETER HALLE
Senior Vice President, Head of TIP Immuno Oncology and Head of External Innovation
Merck KGaA
JOERN-PETER HALLE
Senior Vice President, Head of TIP Immuno Oncology and Head of External Innovation
Merck KGaA

Joern-Peter Halle serves as Senior Vice President, Head of Translational Innovation Platform Immuno-oncology (TIP IO) and Head of External Innovation at Merck, Darmstadt, Germany.

Peter is a member of the R&D Executive Leadership Team and represented as a member of the Discovery Review Committee (DRC) and of the Development Decision Group (DDG).

Peter is leading the TIP IO with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and is a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC.

Most recently, he was Head of the President’s Office and of Strategy and Business operations in healthcare. Prior to this, he was responsible for the program leaders of the clinical oncology portfolio and Head of Early Stage Licensing. He started his career in Merck KGaA 14 years ago as a member of the corporate development team and was member of the Serono acquisition and integration team.

Prior to joining Merck KGaA, Darmstadt, Germany Peter served as Chief Business Officer and the Director and Co-Founder of R&D at Switch Biotech AG. Prior to those roles, he was Principal Founder at JPH, a bioinformatics consultancy firm and a postdoc in biochemistry at the Gene Center Munich. Peter received his Ph.D. in molecular biology from the University of Konstanz.

HONG WAN
HONG WAN
Chief Scientific Officer
ALX Oncology
HONG WAN
Chief Scientific Officer
ALX Oncology

Dr. Hong Wan is a scientific and clinical development leader with over 19 years of experience in biotech and pharmaceutical industry, with broad drug development experience and expertise in multiple therapeutics areas, including Oncology, Immuno-Oncology, Autoimmune diseases, Cardiovascular and metabolic diseases, Neurodegenerative diseases and Ophthalmology.

Dr. Hong Wan is currently Chief Scientific Officer at ALX Oncology, a clinical-stage immune-oncology company. Dr. Wan previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Dr. Wan held previous leadership roles in Clinical Translational Medicine and Discovery Research at Pfizer, Wyeth Research, and Renovis.

Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.

WALTER FERLIN
WALTER FERLIN
Head of Exploratory Science and Translational Medicine
Novimmune
WALTER FERLIN
Head of Exploratory Science and Translational Medicine
Novimmune
KIPP WEISKOPF
KIPP WEISKOPF
Physician/Scientist, Hematology/Oncology fellow
Dana-Farber Cancer Institute
KIPP WEISKOPF
Physician/Scientist, Hematology/Oncology fellow
Dana-Farber Cancer Institute

Kipp Weiskopf, M.D., Ph.D is a clinical fellow in Hematology and Oncology at the Dana-Farber Cancer Institute in Boston, MA. He earned his medical and graduate degrees at Stanford University in the Medical Scientist Training Program. As a member of the laboratory of Irving Weissman, M.D., he characterized the CD47/SIRPα interaction as a myeloid immune checkpoint. He developed engineered SIRPα variants that augment macrophage phagocytosis of cancer and serve as universal enhancers of tumor-opsonizing therapeutic antibodies. He further demonstrated that CD47-blocking therapies can be effective for small cell lung cancer and that CD47-blocking therapies can permit bone marrow transplantation without chemotherapy or radiation. Weiskopf has also developed anti-SIRPα antibodies and showed they enhance phagocytosis in response to tumor-opsonizing antibodies. He further demonstrated that the CD47/SIRPa axis is conserved across evolutionary barriers. More recently, he identified a role for MHC class I molecules as regulators of macrophage activation. Weiskopf is a co-Founder of ALX Oncology, and technology he developed has been licensed to Forty Seven, Inc.

Weiskopf completed his medical training in Internal Medicine Residency Program at Brigham and Women’s Hospital in Boston. He has been awarded the Winston Churchill Scholarship, an NCI Ruth L. Kirschstein NRSA Fellowship, the Harold M. Weintraub Graduate Student Award, the Joanna M. Nicolay Melanoma Foundation Research Scholar Award, and first place in the 2013 Collegiate Inventors Competition. He delivered the PEGS 2018 Young Scientist Keynote address. His ongoing research interests lie in identifying novel myeloid immune checkpoints that regulate macrophage activation within the tumor microenvironment.

STEPHANIE DOUGAN
STEPHANIE DOUGAN
Assistant Professor
Dana-Farber Cancer Institute | Harvard Medical School
STEPHANIE DOUGAN
Assistant Professor
Dana-Farber Cancer Institute | Harvard Medical School

Stephanie Dougan received her PhD in Immunology from Harvard University where she studied lipid antigen presentation by CD1d and NKT cell development. She then performed a postdoctoral fellowship with Hidde Ploegh at Whitehead Institute, where she became adept in somatic cell nuclear transfer and embryo manipulations for the purpose of generating transnuclear and CRISPR genome-modified mice.

Dr. Dougan joined the faculty at Harvard Medical School and Dana-Farber Cancer Institute in 2014, where her lab uses unique mouse models to study the immune response to tumors. She is particularly interested in tumors that do not induce a CD8 T cell response at baseline and has been using pancreatic cancer as a model to develop new immunotherapies for non-T cell infiltrated tumors.

Dr. Dougan is a Pew-Stewart Scholar in Cancer Research, a Bill and Melinda Gates Global Health Innovation Scholar, a
Melanoma Research Alliance Young Investigator, and received a Pathway to Leadership Award from the Pancreatic Cancer Action Network and AACR.

NICOLAS POIRIER
NICOLAS POIRIER
Chief Scientific Officer
OSE Immunotherapeutics
NICOLAS POIRIER
Chief Scientific Officer
OSE Immunotherapeutics

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, where he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.

EMMANUEL NORMANT
EMMANUEL NORMANT
Vice President, Preclinical Sciences
TG Therapeutics
EMMANUEL NORMANT
Vice President, Preclinical Sciences
TG Therapeutics

Emmanuel Normant is currently the VP of Preclinical Sciences at TG Therapeutics, where he leads the efforts on the 3 assets in the early pipeline. These assets include a novel BTK inhibitor, an anti-PD-L1 antibody and a bispecific antibody directed against CD19 and CD47. They are all three in phase 1 dose escalation clinical trials in hematologic cancers.

Dr Normant, after 2 years at Surface Oncology, working on an IgG4 mAb, joined TG Therapeutics, bringing in 20 years expertise in cancer biology, pharmacology, I-O, cancer epigenetic and preclinical sciences.

Emmanuel Normant received his Pharmacy and PhD degrees from the Paris-Sorbonne University.

BOB UGER
BOB UGER
Chief Scientific Officer
Trillium Therapeutics
BOB UGER
Chief Scientific Officer
Trillium Therapeutics

Dr. Uger has spent the past 18 years developing novel agents targeting the immune system. He began his industry career in cancer vaccine research with Aventis Pasteur, and then joined start-up Trillium Therapeutics (private company) as Director, Research & Development, later serving as Vice President, R&D. At Trillium, Dr. Uger has overseen the growth of the company’s pipeline and guided several compounds from concept to the clinic. His expertise spans both innate and adaptive immunology, and he has overseen programs in the fields of immuno-oncology, autoimmunity and transplantation. He received his Ph.D. in immunology from the University of Toronto.

ANDRE VEILLETTE
ANDRE VEILLETTE
Professor, Department of Medicine
University of Montreal
ANDRE VEILLETTE
Professor, Department of Medicine
University of Montreal
MARK CHAO
MARK CHAO
Co-Founder & Vice President of Clinical Development
Forty Seven Inc.
MARK CHAO
Co-Founder & Vice President of Clinical Development
Forty Seven Inc.
SOPHIA RANDOLPH
SOPHIA RANDOLPH
Chief Medical Officer
ALX Oncology
SOPHIA RANDOLPH
Chief Medical Officer
ALX Oncology
TAYLOR SCHREIBER
TAYLOR SCHREIBER
Chief Scientific Officer
Shattuck Labs
TAYLOR SCHREIBER
Chief Scientific Officer
Shattuck Labs

Taylor co-founded Shattuck Labs and currently serves as Chief Scientific Officer and is a member of the Board of Directors. Taylor is the lead inventor of Shattuck’s ARC technology platform.

Prior to Shattuck, Taylor served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. He was also the co-inventor of TNFRSF25 agonist technology developed by Pelican Therapeutics, where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, Taylor received the best overall research award at the National Student Research Forum and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research.

Taylor received his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.

ADAM FOLEY-COMER
ADAM FOLEY-COMER
Chief Medical Officer
KAHR Medical
ADAM FOLEY-COMER
Chief Medical Officer
KAHR Medical
JANE LAMERDIN
JANE LAMERDIN
Director, Research and Development
Eurofins DiscoverX
JANE LAMERDIN
Director, Research and Development
Eurofins DiscoverX

Dr. Lamerdin leads a diverse group of scientists responsible for the development of novel cell-based assays for discovery as well as qualification of bioassays for lot release and neutralizing antibody applications.

Jane has over 19 years of experience in industry generating cell-based assays to support large and small molecule drug discovery, particularly in the oncology, immune-oncology and inflammation therapeutic areas.

She received her Ph.D. from the University of California, Davis in Genetics, and has broad expertise in molecular and cellular biology, systems biology/signal transduction, high throughput screening, high content imaging, and diverse reporter and phenotypic assay formats.

TIMO VAN DEN BERG
TIMO VAN DEN BERG
Professor of Immunology, Head Department of Blood Cell Research
Sanquin Research and Amsterdam University Medical Centre
TIMO VAN DEN BERG
Professor of Immunology, Head Department of Blood Cell Research
Sanquin Research and Amsterdam University Medical Centre

Timo and his group were among the pioneering groups to describe the cloning of the inhibitory receptor SIRPa and the first to describe its myeloid-restricted expression

Timo has since been studying the physiological functions of the CD47/SIRPa interaction and co-discovered its immune checkpoint function.

Timo has been working alongside Synthon Biopharmaceuticals BV to develop agents to target the CD47/SIRPa interaction.

Timo received his MSc in Cell Biology from the University of Amsterdam in 1988 and his PhD in Cell Biology and Immunology in 1992 from Vrije University, Amsterdam.

STEFAN JELLBAUER
STEFAN JELLBAUER
Technical Liaison
Mitra Biotech
STEFAN JELLBAUER
Technical Liaison
Mitra Biotech

Dr. Stefan Jellbauer is the Technical Specialist for Translational Applications and works with clients to craft custom solutions for their drug development needs. He supports the Biopharma Business Development side of Mitra Biotech. After 10 years in academic research he joined Affymetrix/eBioscience, where he worked in the roles of Field Application Scientist and Technical Specialist with Affymetrix and Thermo Fisher Scientific. He joined Mitra Biotech in May 2018.

Dr. Jellbauer received his Ph.D. in Biology from Ludwig-Maximilians University in Munich (Germany), focusing on tumor vaccination. He completed his post-doctoral work at the University of California, Irvine studying mucosal immunology and host-pathogen interactions.

TIM ZHENG
TIM ZHENG
Executive Director, Immune Modulation
Boehringer Ingelheim
TIM ZHENG
Executive Director, Immune Modulation
Boehringer Ingelheim
SERGIO TROMBETTA
SERGIO TROMBETTA
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim
SERGIO TROMBETTA
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim

2019 Agenda

  • Wednesday, April 17th
Wednesday, April 17th
8.00
Registration, Breakfast & Networking
9.00
Chair’s Opening Remarks & Setting the Scene

Kipp Weiskopf, Physician/Scientist, Hematology/Oncology Fellow, Dana-Farber Cancer Institute

9:10
Keynote Presentation: CD47/SIRPα: Why this Pathway, Why Now and the Importance of Collaboration

Mark Chao, Co-Founder & Vice President of Clinical Development, Forty Seven Inc.

9:35
Presentation: Capturing Drug-Induced Modulation of the Tumor Microenvironment Using A Personalized Ex Vivo Histoculture Approach

Stefan Jellbauer, Technical Liaison, Mitra Biotech

10:00
Panel Discussion and Open Q&A: Understanding the Fundamental Biology of the CD47/SIRPα Checkpoint

Moderator: Kipp Weiskopf, Physician/Scientist, Hematology/Oncology Fellow, Dana-Farber Cancer Institute
Walter Ferlin, Head of Exploratory Science and Translational Medicine, Novimmune
Andre Veillette, Professor, University of Montreal
Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim
Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research and Amsterdam University Medical Center

10:40
Morning Refreshments & Networking

Targeting CD47 vs. SIRPα
Deep-Dives into the Different Approaches

11.15
Case Study 1 – Looking at Trillium Therapeutics Approach to Targeting CD47

Bob Uger, Chief Scientific Officer, Trillium Therapeutics

11:40
Case Study 2 – An Insight into ALX Oncology’s Approach to Targeting CD47-SIRPα pathway

Hong Wan, Chief Scientific Officer, ALX Oncology

Breaking the Mould and Targeting SIRPα

12:05
Case Study 3 – A Look into OSE Immunotherapeutics Approach to Targeting SIRPα

Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics

12:30
Panel discussion and Open Q&A: Targeting CD47 vs SIRPα: Is there an Optimal Approach for Targeting the CD47/SIRPα Axis?

Moderator: Tim Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim
Mark Chao, Co-Founder and Vice President of Clinical Development, Forty Seven Inc.
Bob Uger, Chief Scientific Officer, Trillium Therapeutics
Hong Wan, Chief Scientific Officer, ALX Oncology
Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics

1:10
Lunch & Networking
2:10
Presentation: Using a Bispecific Antibody Approach to Target CD47 blockade on Tumor Cells

Walter Ferlin, Head of Exploratory Science and Translational Medicine, Novimmune

2:35
Presentation: Development of a Ready-to-use, MOA Reflective, Cell-Based Signalling Assay for Characterization and Potency Determination of anti-CD47 Therapeutics

Jane Lamerdin, Director of Research and Development, Eurofins DiscoverX

A Pre-Clinical and Translational Focus

3:00
A Pre-Clinical and Translational Focus

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute | Harvard Medical School

3:25
Presentation: An Insight into TG Therapeutics and their Work Leading up to Clinical Trials

Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics

The Next Generation of CD47/SIRPα Approaches

3:50
Presentation: Looking at the Next Generation Approaches of KAHR Medical

Adam Foley-Comer, Chief Medical Officer, KAHR Medical

4:15
Afternoon Refreshments and Networking
4:55
Presentation: Development and Characterization of SL-172154 (SIRPα-Fc-CD40L)

Taylor Schreiber, Chief Scientific Officer, Shattuck Labs

5:20
Panel Discussion and Open Q&A: The Ins and Outs of Monotherapy and Combination Therapy Approaches with CD47/SIRPα

Moderator: Bob Uger, Chief Scientific Officer, Trillium Therapeutics
Kipp Weiskopf, Physician/Scientist, Hematology/Oncology fellow, Dana-Farber Cancer Institute
Sophia Randolph, Chief Medical Officer, ALX Oncology
Joern-Peter Halle, Senior Vice President, Head of TIP Immuno Oncology and Head of External Innovation, Merck KGaA

6:00
Chair’s Closing Remarks

Kipp Weiskopf, Physician/Scientist, Hematology/Oncology Fellow, Dana-Farber Cancer Institute

Close of CD47/SIRPa Summit 2019

Partnership

Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships.  To facilitate this (and help us to fund the event) we have a limited number of partnership opportunities. This means that our partners can be confident they can have the meaningful conversations they seek – and our attendees know that the composition of the audience is just right.

We invite you to get in touch for a no-obligation conversation.  We will share our audience data with you and help you determine whether this summit is the right fit for you.

Contact Us +
Partnership

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration